中国网财经2月25日讯 强生公司今天宣布,特诺雅达(古塞奇尤单抗注射液(静脉输注))和特诺雅(古塞奇尤单抗注射液)已在中国获得批准,用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性克罗恩病成人患者。强生表示,这一加速审批得益于国家药品监督管理局对本品突破性疗法及优先审评的认定,标志着古塞奇尤单抗在克罗恩病适应症上的全球首个批准。据了解,作为唯一具有双重作用机制的白介素23...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.